Pravastatin use was associated with a significant decrease in total cholesterol , low density lipoprotein ( LDL ) cholesterol and LDL particle number levels , but was not associated with any significant changes in cognition or psychopathology in the participants , except a significant decrease in the Positive and Negative Syndrome Scale ( PANSS ) positive symptom score from baseline to week 6 .